A substantial increase in the CD8+ T-cell/eTreg cell ratio was noted in patients undergoing anti-PD-1 therapy, which was linked to a significant increase in the frequency of CD8+ T-cells and a simultaneous reduction in the frequency of eTreg cells within tumor-infiltrating lymphocytes. The gene discussed is CD8A; the disease is neoplasm.